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E-mail addresses: oliver.baum@ana.unibe.ch, baumIn skeletal muscles, the expression of neuronal NO synthase (nNOS) isoforms is uncharacterized at
the protein level. We therefore conducted epitope mapping with anti-peptide-antibodies. Antibod-
ies speciﬁc for the nNOS N-terminus recognized the 160-kDa alpha-isoform. In contrast, antibodies
against the middle portion or the C-terminus of nNOS bound additionally to the truncated 140-kDa
beta-isoform which lacks the PDZ-domain present in the alpha-isoform. All nNOS immunohisto-
chemical reactivity was conﬁned to the sarcolemma. Consistently, immunoblotting disclosed both
nNOS-isoforms to be co-enriched in the membrane-associated fractions. The beta-isoform was co-
immunoprecipitated with alpha-isoform antibodies in muscle extracts indicating an association
of both nNOS-isoforms to direct the beta-variant to the sarcolemma.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
In skeletal muscles, the gaseous radical nitric oxide (NO⁄, NO) is
generated mainly by the catalytic activity of neuronal NO synthase
(nNOS), which is highly expressed at the sarcolemma of the muscle
ﬁbers [1].
Many functions have been assigned to nNOS within skeletal
muscle (reviewed in [2]). As an autocrine signalling molecule,
nNOS-derived NO hinders the depletion of energy stores, supports
anaplerotic reactions and inhibits glycolysis [3]. In addition, nNOS
generated NO is also involved in the scavenging of reactive oxygen
species [4,5]. Furthermore, nNOS-derived NO also plays a role in
paracrine signalling, thus facilitating the interaction between skel-
etal muscle ﬁbers and the adjacent microvasculature [6].
Of the three NOS-genes, only nNOS possesses an N-terminal
PDZ-domain, which facilitates its integration into the dystrophin
glycoprotein complex and its targeting to the sarcolemma [7]. In
patients suffering from Duchenne’s muscular dystrophy, the
nNOS-containing dystrophin glycoprotein complex is down-
regulated. Consequently, the involvement of nNOS in the etiology
of this disease is discussed [8].chemical Societies. Published by E
nitric oxide synthase; TA,
@ana.unibe.ch (O. Baum).At the mRNA level, various isoforms of nNOS have been de-
tected in skeletal muscle [9,10]. Far less is known about the expres-
sion patterns of nNOS-variants at the protein level. Although the
160-kDa alpha and the 140-kDa beta isoforms of nNOS are known
to be co-expressed in skeletal muscles of rats [11], biochemical
analysis as yet has not been gone beyond an establishment of this
fact.
The aim of the present study was to analyze the protein expres-
sion patterns of nNOS-isoforms in skeletal muscle of C57BL/6 mice
using three antibodies against distinct peptide sequences in the
primary structure of nNOS. We also characterized the subcellular
localization and pinpointed the assemblage of the alpha- and
beta-isoforms of nNOS in skeletal muscles.
2. Materials and methods
2.1. Antibodies and recombinant protein
Polyclonal antibodies raised against deﬁned peptides in the rat
nNOS sequence and cross-reacted with murine nNOS were
employed (Fig. 1A): antibody Ab-1 (K-20, Santa Cruz, Heidelberg,
Germany) speciﬁcally recognizing amino acids 38–57 in the N-
terminal region, antibody Ab-2 (N-7155, Sigma, Munich, Germany),
which is speciﬁc for aminoacids 251–270andAb-3 (N-7280, Sigma),
which speciﬁcally identiﬁes amino acids 1409–1429 in the C-termi-
nal region [12].lsevier B.V. All rights reserved.
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Fig. 1. Epitope-mapping of nNOS-isoforms at the protein level in skeletal muscle of C57Bl/6-mice. (A) Three peptide-speciﬁc, polyclonal antibodies were used for the
immunoblotting analysis (Ab-1, Ab-2, Ab-3). (B) Homogenates (40 lg of protein) of the tibialis anterior (TA) muscle, the cerebellum as positive control (Ce) and the liver as
negative control (Li) derived from C57BL/6 mice were subjected to immunoblotting with the anti-nNOS antibodies.
3220 O. Baum et al. / FEBS Letters 585 (2011) 3219–3223A monoclonal antibody against the peptide sequence compris-
ing amino acids 1–181 (N-2280, Sigma) was also used (MAb1-181).
Recombinant rat nNOS (201–028, Biogene-Alexis, Grünberg,
Germany) was employed as positive control in the immunoblotting
analysis.
2.2. Animals and tissue preparation
Six C57BL/6 wild-type and three nNOS knockout-mice were uti-
lized in this study originally produced by Huang et al. [13]. The
mice were bred in our animal-care facility under standard condi-
tions, as previously described [14]. The mice were sacriﬁced in
accordance to the university and state authority approvals.
2.3. Preparation of homogenates and subcellular fractions from
skeletal muscle
Tissue extracts were prepared after solubilization with 1%
Triton X-100 in the presence of protease inhibitors, as previously
described [5].Mr x 10-3
0 1 2 4 16 24Incubation
time
at 37°C 
(hrs)
A
205 -
125 -
100 -
50 -
Mr x
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subcellular fractions, which were isolated from the tibialis anterior
(TA) muscle of C57BL/6 mice. TA specimens were suspended in
phosphate-buffered saline (PBS), pH 7.4, and crushed at 4 C with
a Sorvall Potter (10 strokes). The TA homogenate was then centri-
fuged at 20000g for 20 min in a Kontron H-401 centrifuge. After
removing the supernatant, which compromised the soluble cyto-
plasmic fraction, the pellet was extracted in solubilization buffer
for 1 h at 4 C to yield the crude membrane fraction.
Immunoblotting was performed on subcellular fractions of the
quadriceps muscle, which were prepared by sequential extraction
according to the method originally described by Brenman et al. [7].
2.4. Immunoblotting
Immunoblotting to demonstrate nNOS expression was per-
formed using 50 lg of protein, as previously described [5]. For con-
trol of protein loading, blotting matrices were stained with
Ponceau Red after transfer. The primary antibodies were incubated0 1 2 4 16 240
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nNOS
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lowing dilutions: Ab-1: 1:500; Ab-2 and Ab-3: 1:10000.
2.5. In vitro proteolysis assay
Homogenates (2 mg/ml of protein in PBS, pH 7.4) of TA muscles
from C57BL/6-mice were incubated at 37 C in the absence of
protease inhibitors. At selected time-points (0, 1, 2, 4, 16, 24 h),
aliquots were withdrawn. For the analysis with nNOS knockout-
mice, 0.5 lg of recombinant nNOS was added to 0.5 ml of TA
muscle homogenate (2 mg/ml of protein in PBS, pH 7.4). An aliquot
of the homogenate was removed prior to the addition of the
recombinant protein. All samples were analyzed by SDS–PAGE
and subsequent immunoblotting with Ab-3.
2.6. Immunohistochemistry
10-lm thick cryostat sections were subjected to immunohisto-
chemistry, as previously described [10]. The specimen were incu-
bated overnight at 4 C with phalloidin-rhodamine (Molecular
Probes, Invitrogen, Basel, Switzerland, 1:1000) in combination with
one of the polyclonal anti-nNOS antibodies (Ab-1: 1:50; Ab-2, Ab-
3: 1:1000) and the MAb1-181 (1:1000). Controls were established
by replacing the primary antibodies with blocking buffer.
2.7. Immunoprecipitation
Immunoprecipitation of nNOS was conducted as previously re-
ported [14]. Aliquots of the original TA solubilisate, of the nNOS-
depleted extract and of the antigen/antibody-sepharose pellet
were analyzed by immunoblotting with Ab-2.
3. Results
3.1. Peptide mapping with anti-nNOS-antibodies
The anti-peptide-1 antibody (Ab-1), which is speciﬁc for the N-
terminal region of nNOS (amino acids 38–57), recognized a single
160-kDa protein in the TA muscle solubilisates (Fig. 1B; Supple-
mentary Figs. 1 and 2). If immunoblotting was performed with
the peptide-speciﬁc antibodies against either the middle portion
(amino acids 251–270; Ab-2) or the C-terminal region of nNOS
(amino acids 1409–1429; Ab-3), a 140/160-kDa double-band was
detected in both cases. Occasionally, both bands consisted also of
two double bands slightly differing by 5 kDa (alpha: 165/160 kDa
and beta: 145/140 kDa; Supplementary Fig. 1). These two bands
could represent alpha- and beta-variants with/without exon-mu
or partially depict the gamma isoform of nNOS.
To ascertain whether the beta-isoform of nNOS represents a pro-
teolytic fragmentof the larger alpha-variant,we establishedan in vi-
tro-assay. When the unsolubilized TA homogenates of C57BL/6
wild-type mice were incubated at 37 C in the absence of protease
inhibitors, each nNOS isoform underwent fragmentation (Fig. 2A;
Supplementary Fig. 3). When the same in vitro-assay was also per-
formed using TA homogenates that had been derived from nNOS
knockout-mice and towhich had been added a recombinant protein
of the alpha-isoform, the nNOS-immunoreactive 160-kDa band like-
wise underwent degradation without conversion to the 140-kDa
band (Fig. 2B). High molecular weight bands irregularly detectable
represent presumably protein aggregates containing nNOS.
3.2. Co-localization of the nNOS alpha- and beta-isoforms at the
sarcolemma
The subcellular localization of the alpha- and beta-isoforms of
nNOS in skeletal muscle was pinpointed using three different
methodological approaches.Since immunoreactivity with all anti-nNOS-antibodies was
conﬁned to the sarcolemma (Fig. 3A; Supplementary Fig. 4), we
conclude that the two isoforms are co-localized at this site.
Next, subcellular fractions of the quadriceps muscle that had
been enriched by sequential extraction were subjected to immuno-
blotting with Ab-3 (Fig. 3B; Supplementary Figs. 5 and 6). This
analysis revealed both isoforms of nNOS to be present preferen-
tially in the pellet fraction, which contains the cytoskeleton-asso-
ciated membrane proteins.
Finally, a quantitative dot blot analysis in TA muscles using the
three polyclonal antibodies disclosed comparable protein expres-
sion patterns in the total homogenate (moderate nNOS expres-
sion), in the membrane extract (high nNOS expression) and in
the sarcoplasm fraction (low nNOS expression), as shown in
Fig. 3C.
3.3. Association of the alpha- and the beta-isoforms of nNOS
Immunoprecipitation with Ab-3, which is speciﬁc for the C-ter-
minus of nNOS, resulted in the depletion of both the alpha- and the
beta-isoforms from the TA extract (Fig. 4; Supplementary Fig. 7).
After immunoprecipitation with Ab-1, both isoforms were de-
tected in the pellet. This ﬁnding indicates that the beta-isoform
was co-immunoprecipitated with the alpha-variant due to
association.
4. Discussion
The expression patterns of the distinct nNOS-isoforms have
been predominantly characterized at the mRNA level while the
knowledge on nNOS diversiﬁcation at the protein level is rather
low. Particularly, the beta- and gamma nNOS-variants (in contrast
to the alpha-isoform) have not yet been thoroughly investigated –
a circumstance that reﬂects the non-availability of speciﬁc anti-
bodies against these splice-variants.
By subtraction of the data obtained using an antibody that rec-
ognizes both the alpha- and the beta-isoforms from those obtained
using an antibody that recognizes only the alpha-isoform, it was
gleaned that the beta-isoform of nNOS exhibits an explicit cellular
and subcellular distribution within various regions of the gastroin-
testinal tract of humans [15] and rats [16] partially differing from
that of the alpha-isoform. Far less is known about the expression
proﬁles of nNOS-proteins in skeletal muscle.
Our immunoblotting has revealed nNOS to be expressed as two
major variants in the skeletal muscles of C57BL/6-mice. On the ba-
sis of their molecular weights and the ﬁndings of our epitope map-
ping with the deﬁned peptide-speciﬁc antibodies, the 160-kDa
band can be identiﬁed as the alpha-isoform of nNOS, while the
140-kDa band presumably encodes for the beta-isoform, which
embodies a shorter N-terminus. The alpha/beta-double band was
occasionally again resolved as two separate bands which could
represent alpha- and beta-variants with/without exon-mu or
partially depict the gamma isoform of nNOS.
Recently, Percival et al. [17] have compared the phenotypic char-
acteristics of skeletal muscles derived from mice of the original
nNOS-knockout strain [13] with those of a subsequently-developed
nNOS-knockout strain missing exon-6, which expresses no residual
nNOS protein and activity [18]. A sarcoplasmic localization and a
role in force maintenance of the nNOS beta-isoform was deduced
from the results obtained. However, this interpretation is largely
speculative, since no information respecting the expression of the
beta-isoform in the mice used was furnished at either the mRNA
or protein level.
It remains a matter of speculation why a simultaneous expres-
sion of alpha- and beta-isoforms of nNOS has not been hitherto de-
tected. In some studies, nNOS was disclosed as a single 160-kDa
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Fig. 4. The beta-isoform of nNOS is associated with the alpha-variant. 300 lg of
solubilized protein from TA muscle homogenates of C57BL/6-mice were subjected
to immunoprecipitation with either Ab-1 or Ab-3. Aliquots of the original muscle
solubilisate (S), the nNOS-depleted extract (D) and the immunoprecipitate (IP) were
immunoblotted with Ab-2.
Fig. 3. The alpha- and the beta-isoforms of nNOS are co-localized at the sarcolemma. (A) Immunoﬂuorescence images of cryosections a sarcolemmal localisation of nNOS
alpha- and beta-isoforms in TA muscle. Note the absence of patent immunoreactivity inside the skeletal muscle ﬁbers (displayed with phalloidin-staining; blue signal) after
exposure to MAb1-181 (green signal) and Ab-3 (red signal). In the merge a co-localization of the immunoreactivity is displayed as orange signal. (B) Immunoblotting with Ab-
3 of subcellular fractions revealed the 160-kDa and the 140-kDa isoforms of nNOS to be simultaneously enriched in the detergent-extractable membrane (S3) and cytoskeletal
(P) fractions, but to be absent from the soluble sarcoplasmic (S1) and the membrane-associated (S2) ones. (C) Using Ab-1 (diluted 1:100), Ab-2 (diluted 1:1000) and Ab-3
(diluted 1:1000), a dot blot analysis was performed with equivalent amounts of proteins (y-axis), which were derived from the total homogenate (H), the crude membrane
extract (M) and the soluble sarcoplasmic fraction (S) of the TA muscle from C57BL/6-mice.
3222 O. Baum et al. / FEBS Letters 585 (2011) 3219–3223band but was either enriched with 20,50-ADP-sepharose prior to
immunoblotting [7,12] or use of antibodies against the N-terminus
not recognizing the beta-isoform [6,19]. In other cases, it has not
been possible to ascertain whether a 140-kDa band was present,
since the relevant area of the immunoblots is not depicted [20–
22]. In a third group of studies, an nNOS-immunoreactive dou-
ble-band with a 20-kDa spacing difference is clearly visible on
the immunoblots. If any explanation is offered for the existence
of this second band, it was attributed either to proteolytic diges-
tion [23] or to a non-exon-mu-expressing isoform [3]. This expla-
nation is, however, untenable, since the 34-amino acid-long
exon-mu corresponds to a 5-kDa difference not to one of 20-kDa
in the molecular weight. It is also unlikely that the 140-kDa band
arises from cross-reactivity of the anti-nNOS antibodies with either
iNOS (120-kDa) or eNOS (130-kDa), as we have previously demon-
strated by immunoblotting analysis.An analysis of subcellular fractions that have been enriched by
sequential extraction is a well-established methodological ap-
proach for probing the distribution of nNOS inside the myoﬁbers
of the quadriceps muscle of mice [7,19,24,25]. Our own data have
revealed both the alpha- and the beta-isoforms to be simulta-
neously enriched in the membrane-associated fraction and ex-
pressed at the sarcolemma.
The N-terminus of the alpha-isoform of nNOS contains a hydro-
phobic PDZ-domain, which anchors the enzyme in an active form
at the sarcolemma [26]. Other N-terminal domains of nNOS
embracing amino acids 100–231 have also been implicated in the
sarcolemmal binding of the enzyme [27]. On the basis of the data
derived from our epitope-mapping, the expression of these pre-
sumptive sarcolemma-binding domains in the beta-isoform can
be excluded. Hence, targeting of the sarcolemmamust be mediated
by an alternative mechanism, for example, by interaction with one
of the established nNOS-adaptor proteins.
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